To reduce the risk of developing adverse events, use a minimally effective dose with a short course.
From the digestive system:
more than 1% - abdominal pain, feeling bloated, indigestion, diarrhea, nausea, constipation, flatulence, increased levels of "liver" enzymes, peptic ulcer with possible complications;
less than 1% - dry mouth and mucous membranes, changes in appetite, gastritis, glossitis, esophageal damage, aphthous stomatitis, vomiting, jaundice, proctitis, digestive disorders, non-specific haemorrhagic colitis, gastro-intestinal bleeding, exacerbation of ulcerative colitis or
Crohn's disease, hepatitis (fulminant possible), hepatic necrosis, cirrhosis, hepatorenal syndrome, pancreatitis, holetsistopankreatit, colitis.
From the nervous system:
more often 1% - headache, dizziness;
less than 1% - insomnia, drowsiness, depression, irritability, aseptic meningitis (usually in patients with systemic lupus erythematosus and other connective tissue diseases), cramps, weakness, disorientation, nightmares, feeling of fear; very rarely - a violation of sensitivity, incl. paresthesia, memory disorders, tremor, cerebrovascular disorders, insomnia, mental disorders.
From the sense organs:
more often 1% - vertigo; very rarely - visual impairment (blurred vision, diplopia), hearing impairment, tinnitus, taste disorders;
From the skin:
more often 1% - skin itch, skin rash;
less than 1% - alopecia, urticaria, eczema, toxic dermatitis, multiform exudative erythema, incl. Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), increased photosensitivity melkotochechnye hemorrhage;
very rare - bullous rash, exfoliative dermatitis.
From the genitourinary system:
more often 1% - fluid retention;
less than 1% - nephrotic syndrome, proteinuria, oliguria, hematuria, interstitial nephritis, papillary necrosis, acute renal failure, azotemia.
From the organs of hematopoiesis and the immune system:
less than 1% - anemia (including haemolytic and aplastic anemia), leukopenia, thrombocytopenia, eosinophilia, agranulocytosis, thrombocytopenic purpura, worsening of infectious processes (development of necrotizing fasciitis, pneumonia).
From the respiratory system:
less than 1% - cough, bronchospasm, laryngeal edema, pneumonitis, bronchial
asthma (including dyspnea).
From the cardiovascular system:
less than 1% - increased blood pressure; congestive heart failure, extrasystole, chest pain; very rarely - palpitations, vasculitis, myocardial infarction.
Allergic reactions:
less often 1% - anaphylactoid reactions, anaphylactic shock (usually develops rapidly), swelling of the lips and tongue, allergic vasculitis.
Other:
more often 1% - irritation at the injection site; very rarely - an abscess at the injection site.